Urological
tumours have become one of the most common cancers in the last decade. It is
important to apply an approach that evaluates many factors related to the
patient and the disease carefully to minimize cancer-associated morbidity and mortality.
The clinical use of cancer biomarkers is a valuable part of the clinical management
of urological cancers. These biomarkers may lead to optimized detection, treatment,
and follow-up of urological cancers. With the development of molecular research,
newly developed biomarkers and next-generation sequencing have also contributed
to patient management. In this chapter, we will present biomarkers in the most
common urological cancers under subheadings of bladder cancer, prostate cancer,
kidney cancer, and testicular cancer. Additionally, due to the development that
occurred in the next-generation sequencing (NGS), all the above-mentioned malignancies
are evaluated with regard to NGS.
Keywords: Biomarkers, Clinical management, Molecular research, Nextgeneration sequencing, Patient management, Urological cancers.
